An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)

Exclusion Criteria

• •\- Participants with hyperprolinemia.
• •\- Participants who are receiving the following medications:
• •• Systemic corticosteroids (prednisone or equivalent; average daily dose of greater than \[\>\] 15 mg) from 4 weeks before Screening.
• •• Any dose of systemic immunosuppressants within 9 months or 5 times the half-life (t½) plus 6 months before Screening, whichever is longer.
• •• Any dose of biologic therapies with influence on the immune system (eg, tumor necrosis factor inhibitors, interleukin inhibitors, B-cell inhibitors), including investigational agents, within 12 months or 5 times the t½ plus 6 months before Screening, whichever is longer.
• •• Participants who are currently receiving anti-coagulation therapy.
• •\- Participants with hypoalbuminemia, protein-losing enteropathies, and kidney diseases with proteinuria.
• •\- Participants with a documented history or a current diagnosis of a thromboembolic event(s) (eg, deep vein thrombosis, pulmonary embolism, myocardial infarction, cerebrovascular accident, transient ischemic attack) or coagulopathy within 12 months before Screening.
• •\- Participants with severe dehydration and known blood disorders affecting viscosity.
• •\- Participants with aspartate aminotransferase and alanine aminotransferase concentration \> 3 times the upper limit of normal (ULN; central laboratory) at Screening.
• •\- Participants with creatinine concentration \> 1.5 times the ULN (central laboratory) at Screening.
• •\- Participants with new onset or worsening or severe cardiac, pulmonary, kidney disease, and liver disease.
• •\- Participants with malignancies of lymphoid cells such as chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and immunodeficiency with thymoma.